{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-3953"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-3953","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"Behavioral Effects of Novel Treatments for Pain and Alcohol Use Disorder","abstract":"Opioid use disorder (OUD) and alcohol use disorder (AUD) are pressing public health problems in the United States that require new pharmacotherapies to be explored. Current FDA-approved treatment options for these two disorders are only moderately effective. Thus, there is a demand for the identification of new targets for drug development. Previous research initiatives have shown that when morphine is co-administered with the novel imidazodiazepine, MP-III-024, synergistic effects in models of analgesia and antinociception are produced. Our research efforts were concerned with understanding if morphine in combination with MP-III-024 produced synergistic effects in measures of undesirable pharmacological responses: opioid side effects. The results of our operant self-administration tests demonstrated that MP-III-024 does not enhance morphine induced disruptions; and in models of locomotor function, our 1.0:0.94 morphine:MP-III-024 ratio demonstrated a statistically significant subadditive (anti-synergistic) effect. With these findings, we now know that morphine and MP-III-024 are not universally synergistic. Concerning AUD, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was studied through palatable food self-administration testing. Our results showed that CAB-01-019 did not significantly reduce behavioral responses at any of the three tested doses (10, 17.8, and 30 mg/kg). These palatable food self-administration tests with CAB-01-019 will serve as a critical control for future alcohol tests.","abstract_html":"Opioid use disorder (OUD) and alcohol use disorder (AUD) are pressing public health problems in the United States that require new pharmacotherapies to be explored. Current FDA-approved treatment options for these two disorders are only moderately effective. Thus, there is a demand for the identification of new targets for drug development. Previous research initiatives have shown that when morphine is co-administered with the novel imidazodiazepine, MP-III-024, synergistic effects in models of analgesia and antinociception are produced. Our research efforts were concerned with understanding if morphine in combination with MP-III-024 produced synergistic effects in measures of undesirable pharmacological responses: opioid side effects. The results of our operant self-administration tests demonstrated that MP-III-024 does not enhance morphine induced disruptions; and in models of locomotor function, our 1.0:0.94 morphine:MP-III-024 ratio demonstrated a statistically significant subadditive (anti-synergistic) effect. With these findings, we now know that morphine and MP-III-024 are not universally synergistic. Concerning AUD, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was studied through palatable food self-administration testing. Our results showed that CAB-01-019 did not significantly reduce behavioral responses at any of the three tested doses (10, 17.8, and 30 mg/kg). These palatable food self-administration tests with CAB-01-019 will serve as a critical control for future alcohol tests.","abstract_has_math":false,"creators":["Donegan, Christa Marie"],"institution":null,"degree_name":"Master of Science in Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Thomas M. Keck, Ph.D.","James P. Grinias, Ph.D.","Martin O. Job, Ph.D."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:24Z","subjects":["Alcohol Use Disorder (AUD)","CAB-01-019","CD-1 mice","Morphine","MP-III-024","Opioid Use Disorder (OUD)","Drug development","Drugs--Testing","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/2951","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/2951","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-3953","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Thomas M. Keck, Ph.D.","James P. Grinias, Ph.D.","Martin O. Job, Ph.D."]},{"key":"dc:creator","label":"Author","values":["Donegan, Christa Marie"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-09-30T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2021-09-28T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science in Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Alcohol Use Disorder (AUD)","CAB-01-019","CD-1 mice","Morphine","MP-III-024","Opioid Use Disorder (OUD)","Drug development","Drugs--Testing","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/2951"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Opioid use disorder (OUD) and alcohol use disorder (AUD) are pressing public health problems in the United States that require new pharmacotherapies to be explored. Current FDA-approved treatment options for these two disorders are only moderately effective. Thus, there is a demand for the identification of new targets for drug development. Previous research initiatives have shown that when morphine is co-administered with the novel imidazodiazepine, MP-III-024, synergistic effects in models of analgesia and antinociception are produced. Our research efforts were concerned with understanding if morphine in combination with MP-III-024 produced synergistic effects in measures of undesirable pharmacological responses: opioid side effects. The results of our operant self-administration tests demonstrated that MP-III-024 does not enhance morphine induced disruptions; and in models of locomotor function, our 1.0:0.94 morphine:MP-III-024 ratio demonstrated a statistically significant subadditive (anti-synergistic) effect. With these findings, we now know that morphine and MP-III-024 are not universally synergistic. Concerning AUD, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was studied through palatable food self-administration testing. Our results showed that CAB-01-019 did not significantly reduce behavioral responses at any of the three tested doses (10, 17.8, and 30 mg/kg). These palatable food self-administration tests with CAB-01-019 will serve as a critical control for future alcohol tests."]},{"key":"dc:title","label":"Title","values":["Behavioral Effects of Novel Treatments for Pain and Alcohol Use Disorder"]}]}],"canonical_facts":{"dc:contributor":["Thomas M. Keck, Ph.D.","James P. Grinias, Ph.D.","Martin O. Job, Ph.D."],"dc:creator":["Donegan, Christa Marie"],"dc:date.available":["2022-09-30T07:00:00Z"],"dc:date.created":["2021-09-28T07:00:00Z"],"dc:description.abstract":["Opioid use disorder (OUD) and alcohol use disorder (AUD) are pressing public health problems in the United States that require new pharmacotherapies to be explored. Current FDA-approved treatment options for these two disorders are only moderately effective. Thus, there is a demand for the identification of new targets for drug development. Previous research initiatives have shown that when morphine is co-administered with the novel imidazodiazepine, MP-III-024, synergistic effects in models of analgesia and antinociception are produced. Our research efforts were concerned with understanding if morphine in combination with MP-III-024 produced synergistic effects in measures of undesirable pharmacological responses: opioid side effects. The results of our operant self-administration tests demonstrated that MP-III-024 does not enhance morphine induced disruptions; and in models of locomotor function, our 1.0:0.94 morphine:MP-III-024 ratio demonstrated a statistically significant subadditive (anti-synergistic) effect. With these findings, we now know that morphine and MP-III-024 are not universally synergistic. Concerning AUD, the dopamine D4 receptor (D4R) full antagonist, CAB-01-019, was studied through palatable food self-administration testing. Our results showed that CAB-01-019 did not significantly reduce behavioral responses at any of the three tested doses (10, 17.8, and 30 mg/kg). These palatable food self-administration tests with CAB-01-019 will serve as a critical control for future alcohol tests."],"dc:identifier":["https://rdw.rowan.edu/etd/2951"],"dc:subject":["Alcohol Use Disorder (AUD)","CAB-01-019","CD-1 mice","Morphine","MP-III-024","Opioid Use Disorder (OUD)","Drug development","Drugs--Testing","Pharmacy and Pharmaceutical Sciences"],"dc:title":["Behavioral Effects of Novel Treatments for Pain and Alcohol Use Disorder"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science in Pharmaceutical Sciences"]},"updated_at":"2026-11-19T08:59:24Z"}